Dr Lewis Quayle
Department of Oncology and Metabolism
Cancer Bioinformatician
+44 114 215 9209
Full contact details
Department of Oncology and Metabolism
Room M120, M Floor
Royal Hallamshire Hospital
Glossop Road
Sheffield
S10 2JF
- Profile
-
I obtained my PhD in the Bone Oncology groups of Prof. Ingunn Holen and Dr Penelope Ottewell in the Department of Oncology & Metabolism at The University of Sheffield. My PhD project focussed on developing novel models of mitotic quiescence and metastatic dormancy in breast cancer and my early postdoctoral work focussed on characterising the cellular sub-populations isolated from these model systems using a multitude of approaches, including next-generation sequencing.
During 2019, I undertook a three-month training placement in high-performance computing (HPC) and bioinformatic analysis of next-generation sequencing data at the Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research (Sydney, Australia) working under Dr Nenad Bartonicek in the Group of Prof. Alex Swarbrick.
Upon my return to The University of Sheffield, I transitioned to a two-year position as a postdoctoral cancer bioinformatician and in June 2022 moved to my current role as cancer bioinformatician embedded within the Sheffield Bioinformatics Core Facility and working in the groups of Prof. James Catto and Dr Dennis Wang.
My role within the Sheffield Bioinformatics Core Facility involves delivery of custom analyses, processed data, experimental results, and reports detailing quality control procedures and analytical workflows to core facility users. I am also involved in supporting the provision of best-practice training and workshops in next-generation sequencing and bioinformatics techniques to laboratory scientists, assisting investigators across the university in statistically sound experimental design, aiding interpretation of results, and grant or manuscript writing where these require extensive bioinformatics input.
- Research interests
-
My current research activity is centred on a project aiming to create a mutational map of the non-coding regions of patient genomes for the bladder cancer arm of the 100,000 Genomes Project. I am also contributing bioinformatics capability to the Genotype of Urothelial Cancer - Stratified Treatment and Oncological outcomes (GUSTO) phase II clinical study. These roles involve contributing to the maintenance of well-curated, highly structured, transparent resources for integrating genomic and clinical data, and assessing, testing, and implementing best practice scalable HPC workflows and methods for genomic data analysis.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Transcriptomic profiling reveals novel candidate genes and signalling programs in breast cancer quiescence and dormancy. Cancers, 13(16). View this article in WRRO
- IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. npj Breast Cancer, 7(1). View this article in WRRO
- Chemotherapy resistance and stemness in mitotically quiescent human breast cancer cells identified by fluorescent dye retention. Clinical and Experimental Metastasis. View this article in WRRO
- Anti-angiogenic drugs: direct anti-cancer agents with mitochondrial mechanisms of action. Oncotarget, 8(51), 88670-88688. View this article in WRRO
- Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer. Current Cancer Drug Targets, 15(6), 469-480.
Chapters
- Stem cell niches in bone and their roles in cancer metastasis, The Cancer Stem Cell Niche (pp. 35-62). Elsevier
- Tumor Dormancy in the Bone In Caplan M (Ed.), Reference Module in Biomedical Sciences Elsevier View this article in WRRO
Conference proceedings papers
- Abstract P10.12: Therapeutic Resistance and Stemness in Mitotically Quiescent Human Breast Cancer Cells. 1st UK Interdisciplinary Breast Cancer Symposium—15th–16th January 2018
- Abstract P3-07-14: Targeting ERR-α regulated lactate metabolism eliminates drug-resistant breast cancer cells. Poster Session Abstracts
All publications
Journal articles
- Transcriptomic profiling reveals novel candidate genes and signalling programs in breast cancer quiescence and dormancy. Cancers, 13(16). View this article in WRRO
- IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. npj Breast Cancer, 7(1). View this article in WRRO
- Chemotherapy resistance and stemness in mitotically quiescent human breast cancer cells identified by fluorescent dye retention. Clinical and Experimental Metastasis. View this article in WRRO
- Anti-angiogenic drugs: direct anti-cancer agents with mitochondrial mechanisms of action. Oncotarget, 8(51), 88670-88688. View this article in WRRO
- Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer. Current Cancer Drug Targets, 15(6), 469-480.
Chapters
- Stem cell niches in bone and their roles in cancer metastasis, The Cancer Stem Cell Niche (pp. 35-62). Elsevier
- Tumor Dormancy in the Bone In Caplan M (Ed.), Reference Module in Biomedical Sciences Elsevier View this article in WRRO
Conference proceedings papers
- Abstract P10.12: Therapeutic Resistance and Stemness in Mitotically Quiescent Human Breast Cancer Cells. 1st UK Interdisciplinary Breast Cancer Symposium—15th–16th January 2018
- Abstract P3-07-14: Targeting ERR-α regulated lactate metabolism eliminates drug-resistant breast cancer cells. Poster Session Abstracts
- Transcriptomic profiling reveals novel candidate genes and signalling programs in breast cancer quiescence and dormancy. Cancers, 13(16). View this article in WRRO
- Professional activities and memberships
-
I am currently a member of the British Association for Cancer Research (BACR), the European Association for Cancer Research (EACR), the Institute of Biomedical Science (IBMS) and the Royal Society of Biology (RSB).